At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
Docosahexaenoic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
In Brief
A Phase 2 clinical trial evaluating Docosahexaenoic Acid and Placebo for Benign Breast Neoplasm and 11 related conditions. Completed, enrolled 65 participants across 4 sites.
Detailed Summary
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionJan 2016
Study CompletionApr 2020
TodayJul 2026
First PostedMay 8, 2013
Enrollment StartMay 1, 2013
Primary CompletionJan 11, 2016
Study CompletionApr 22, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.2 years ago
Interventions
Docosahexaenoic Aciddrug
Given PO
Placeboother
Given PO